<DOC>
	<DOCNO>NCT00091377</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin paclitaxel , work different way stop tumor cell divide stop grow die . Phenoxodiol may help cisplatin paclitaxel kill tumor cell make tumor cell sensitive drug . PURPOSE : This randomized phase I/II trial study side effect phenoxodiol give together either cisplatin paclitaxel see well work treat patient recurrent late-stage ovarian epithelial cancer , fallopian tube cancer , primary peritoneal cancer respond treatment drug paclitaxel , docetaxel , cisplatin , carboplatin .</brief_summary>
	<brief_title>Phenoxodiol Combined With Either Cisplatin Paclitaxel Patients With Recurrent Ovarian Epithelial , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare safety tolerability phenoxodiol combine cisplatin paclitaxel patient recurrent late-stage ovarian epithelial , fallopian tube , primary peritoneal cancer refractory resistant platinum and/or taxane drug . - Compare , preliminarily , tumor response patient treat regimen . OUTLINE : This open-label , randomize , multicenter study . Patients randomize 1 2 treatment arm accord medical history . - Arm I : Patients receive phenoxodiol IV 10 minute day 1 2 cisplatin IV 1 hour day 2 . - Arm II : Patients receive phenoxodiol arm I paclitaxel IV 1 hour day 2 . In arm , treatment repeat every 6 week 8 course absence disease progression unacceptable toxicity . Quality life assess 12 , 24 , 36 , 48 week end study participation . Patients follow 6 12 month . PROJECTED ACCRUAL : A total 40 patient ( 20 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial , fallopian tube , primary peritoneal cancer Recurrent disease Received 4 prior chemotherapy regimen malignancy Considered refractory resistant prior taxane ( paclitaxel docetaxel ) and/or platinum ( cisplatin carboplatin ) therapy base 1 follow criterion : Treatmentfree interval &lt; 6 month platinum paclitaxel Disease progression platinum paclitaxelbased therapy Measurable evaluable disease Measurable disease define least 1 unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Evaluable disease define double CA 125 blood level within past 6 month AND CA 125 level ≥ 2 time upper limit normal ( ULN ) within past week No active CNS metastases Patients know CNS metastasis must receive prior radiotherapy CNSdirected chemotherapy AND ≥ 4 week stable disease PATIENT CHARACTERISTICS : Age Over 18 Performance status Karnofsky 60100 % Life expectancy At least 3 month Hematopoietic Neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 WBC &gt; 3,000/mm^3 Hematocrit ≥ 28 % ( transfusion growth factor allow ) Hemoglobin &gt; 8.0 g/dL ( transfusion growth factor allow ) Hepatic Bilirubin ≤ 1.5 time ULN SGOT ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Renal Creatinine ≤ 1.5 time ULN Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active infection require antibiotic No neuropathy ( sensory motor ) &gt; grade 1 PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy Chemotherapy See Disease Characteristics No concurrent chemotherapy Endocrine therapy No concurrent hormonal therapy malignancy Radiotherapy See Disease Characteristics No prior whole abdominal radiotherapy Concurrent localize radiotherapy allow control local complication indicative general disease progression Surgery Not specify Other Recovered prior antineoplastic therapy More 4 week since prior standard therapy malignant tumor More 6 month since prior investigational anticancer drug No concurrent investigational drug No concurrent drug significantly metabolize cytochrome P450 enzymes CYP2C8 , CYP2C9 , CYP2C19 , CYP3A4/B1C No concurrent amifostine protective agent No concurrent grapefruit juice</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
</DOC>